Back to search

Japan· JP-3992400A3045

アデノシン三リン酸二ナトリウム水和物

A adenosine product containing アデノシン三リン酸二ナトリウム水和物, registered in Japan by 興和, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

On Japan’s NHI price listATC C01EB10

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedアデノシン三リン酸二ナトリウム水和物ATCC01EB10REGISTER NO.JP-3992400A3045PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Adenosine is registered in 16 of 19 countries.

Countries holding a registration under ATC C01EB10 (adenosine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 8 of them publish a price we can compare per daily dose

Adenosine · ATC C01EB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
アデノシン三リン酸二ナトリウム水和物
Manufacturer
興和
Country
Japan (JP)
ATC code
C01EB10
ATC class
Adenosine
Defined daily dose
15 mg, P
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

181 interactions on record for adenosine.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Adenosine · interactions on record

181 records

  • 38 severe
  • 90 moderate
  • 1 minor
  • 52 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Adenosine in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All adenosine products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • France · Striadyne

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c1005a5c-2964-42b4-aceb-46b28114f361
GET /v1/drugs/c1005a5c-2964-42b4-aceb-46b28114f361?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "40mg1管",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "3992400A3045",
  "category": "注射薬",
  "price_yen": 70,
  "generic_name": "アデノシン三リン酸二ナトリウム水和物",
  "product_name_jp": null,
  "therapeutic_class": "3992",
  "transitional_expiry": null
}

See everything about adenosine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.